tbuckley/cabot-search huggingface dataset:
Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems
Authors: Wei How Lim
Journal: JAMA (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems
Authors: Peng Luo, Anqi Lin, Kai Miao
Journal: JAMA (2025)

To the Editor A recent article1 demonstrated an increased breast cancer risk associated with the LNG-IUS in comparison with nonusers of hormonal contraceptives. While this study provides valuable insights, we have concerns about the lack of dose-stratified analysis.
Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems
Authors: Mathilde Marie Brünnich Sloth, Terese Sara Høj Jørgensen, Anne-Marie Nybo Andersen
Journal: JAMA (2025)

To the Editor We are concerned that some of the methodological approaches in a recent study1 linking use of LNG-IUSs to increased risk of breast cancer may lead to spurious associations and limit the generalizability of the results outside of the selected subpopulation in the study.
Systematic mining and quantification reveal the dominant contribution of non-HLA variations to acute graft-versus-host disease
Authors: Shuang Liang, Yu-Jian Kang, Mingrui Huo, De-Chang Yang, Min Ling, Keli Yue, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Chen-Rui Xia, Jing-Yi Li, Ning Wu, Ruoyang Liu, Xinyu Dong, Jiangying Liu, Ge Gao, Xiao-Jun Huang
Journal: Cellular and Molecular Immunology (2025)
Distant origin of glioblastoma recurrence: neural stem cells in the subventricular zone serve as a source of tumor reconstruction after primary resection
Authors: Xue Li, Hyun Jung Kim, Jihwan Yoo, Yeonhee Lee, Chang Hyun Nam, Jonghan Park, Soon-Tae Lee, Tae Min Kim, Seung Hong Choi, Jae-Kyung Won, Sung‑Hye Park, Young Seok Ju, Jong Bae Park, Se Hoon Kim, Jong Hee Chang, Hong-Gyun Wu, Chul-Kee Park, Jeong Ho Lee, Seok-Gu Kang, Joo Ho Lee
Journal: Molecular Cancer (2025)
Kidney-targeting DNA tetrahedral molecular cage synergistically inhibits acute kidney injury by clearing ROS and activating HO-1
Authors: Yu Ren, Yuhang Dong, Zhi Li, Keying Xu, Jiafeng Xu, Xiangyu Li, Mengmeng Zhang, Changlu Xu, Min Yang, Min Lee, Xiaoming Meng, Jie Wang
Journal: Biomaterials (2025)
Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines
Authors: Liudmyla Maksymova, Yannick A. Pilger, Lutz Nuhn, Jo A. Van Ginderachter
Journal: Molecular Cancer (2025)

Among the emerging strategies for cancer theranostics, nanomedicines offer significant promise in advancing both patients' diagnosis and treatment. In combination with nanobodies, nanomedicines can potentially enhance the precision and efficiency of drug or imaging agent delivery, addressing key limitations of current approaches, such as off-target toxicities. The development of nanomedicines will be further accelerated by the creation of smart nanoparticles, and their integration with immunotherapy. Obviously, the success of nano-immunotherapy will depend on a comprehensive understanding of the tumor microenvironment, including the complex interplay of mechanisms that drive cancer-mediated immunosuppression and immune escape. Hence, effective therapeutic targeting of the tumor microenvironment requires modulation of immune cell function, overcoming resistance mechanisms associated with stromal components or the extracellular matrix, and/or direct elimination of cancer cells. Identifying key molecules involved in cancer progression and drug resistance is, therefore, essential for developing effective therapies and diagnostic tools that can predict patient responses to treatment and monitor therapeutic outcomes. Current nanomedicines are being designed with careful consideration of factors such as the choice of carrier (e.g., biocompatibility, controlled cargo release) and targeting moiety. The unique properties of nanobodies make them an effective engineering tool to target biological molecules with high affinity and specificity. In this review, we focus on the latest applications of nanobodies for targeting various components of the tumor microenvironment for diagnostic and therapeutic purposes. We also explore the main types of nanoparticles used as a carrier for cancer immunotherapies, as well as the strategies for formulating nanoparticle-nanobody conjugates. Finally, we highlight how nanobody-nanoparticle formulations can enhance current nanomedicines.
Protein S Genomics and Proteomics Refine Thrombosis Risk
Authors: Margaret V. Ragni
Journal: JAMA (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A noninvasive realtime body position monitoring system for the entire course of tumor radiotherapy
Authors: Jiong Shu, Jingyuan Shao, Lingling Liu, Xiang Huang, Yuxiang Mao, Huabao Chen, Xiangli Cui, Bingbing Li, Jie Jia, Zhenle Fei, Zongtao Hu, Xianjun Yang, Yannan Chu, Hongzhi Wang
Journal: npj Digital Medicine (2025)

In tumor radiotherapy, monitoring patient body position is crucial for improving efficacy and reducing complications. We developed a contact-based body position monitoring system using pressure sensors and artificial intelligence, enabling non-invasive, radiation-free, real-time monitoring. The system consists of two pressure-sensitive mattresses with 6400 piezoresistive pressure points each, placed under the scapulae and sacrococcygeal region to monitor resistance values for center of gravity calculation. Using data from 251 cancer patients across 1046 sessions, a random forest algorithm achieved an area under the curve (AUC) of 0.995. Internal validation revealed a true positive rate (TPR) of 95.5% and accuracy (ACC) of 96.8%. Overall accuracy exceeded 90%, providing an effective and low-cost solution for continuous body position monitoring during radiotherapy.
Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems
Authors: Carolyn L. Westhoff, Malcolm C. Pike, Celeste Leigh Pearce
Journal: JAMA (2025)

To the Editor A recent Research Letter1 concluded that levonorgestrel-releasing intrauterine system (LNG-IUS) use increased breast cancer risk to a significant extent, with a similar risk to that reported for current or recent use of other hormonal contraceptives.2
Publisher Correction: An international perspective on the future of systemic sclerosis research
Authors: David J. Abraham, Carol M. Black, Christopher P. Denton, Jörg H. W. Distler, Robyn Domsic, Carol Feghali-Bostwick, Pravitt Gourh, Monique Hinchcliff, Fred Kolling, Masataka Kuwana, Robert Lafyatis, Ulf Landegren, J. Matthew Mahoney, Javier Martin, Marco Matucci-Cerinic, Zsuzsanna H. McMahan, Ana L. Mora, Luc Mouthon, Marlene Rabinovitch, Mauricio Rojas, Kristofer Rubin, Maria Trojanowska, John Varga, Michael L. Whitfield, Armando Gabrielli, Thomas Krieg
Journal: Nature Reviews Rheumatology (2025)
Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients
Authors: Rohin K Reddy, James P Howard, Michael J Mack, Michael J Reardon, Troels Højsgaard Jørgensen, Hans Gustav Hørsted Thyregod, William D Toff, Nicolas M Van Mieghem, Amit N Vora, Raj R Makkar, Samir Kapadia, John K Forrest, Martin B Leon, Yousif Ahmad
Journal: Journal of the American College of Cardiology (2025)
Predictors of Outcomes of Reintervention After Transcatheter Aortic Valve Replacement
Authors: Eric Durand, Hélène Eltchaninoff, Didier Tchetche, Thomas Levesque, Cristian Garmendia, Bernard Iung, Hakim Benamer, Guillaume Cayla, Eric Van Belle, Philippe Commeau, Herve Le Breton, Thomas Cuisset, Mariama Akodad, Jean-Philippe Verhoye, Sylvain Beurtheret, Florence du Chayla, Manon Leclere, Martine Gilard, Nicolas Dumonteil
Journal: Journal of the American College of Cardiology (2025)
De Novo Serine Synthesis is a Metabolic Vulnerability that can be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma
Authors: Manon Teisseire, Umakant Sahu, Julien Parola, Meng-Chen Tsai, Valérie Vial, Jérôme Durivault, Renaud Grépin, Yann Cormerais, Clément Molina, Arthur Gouraud, Gilles Pagès, Issam Ben-Sahra, Sandy Giuliano
Journal: Cancer Research (2025)

Abstract Sunitinib is an oral tyrosine kinase inhibitor used in treating advanced renal cell carcinoma (RCC) that exhibits significant efficacy but faces resistance in 30% of patients. Identifying the molecular mechanisms underlying resistance could enable the development of strategies to enhance sunitinib sensitivity. Here, we showed that sunitinib induces a metabolic shift leading to increased serine synthesis in RCC cells. Activation of the GCN2-ATF4 stress response pathway was identified as the mechanistic link between sunitinib treatment and elevated serine production. The increased serine biosynthesis supported nucleotide synthesis and sustained cell proliferation, migration, and invasion following sunitinib treatment. Inhibiting key enzymes in the serine synthesis pathway, such as PHGDH and PSAT1, enhanced the sensitivity of resistant cells to sunitinib. Beyond RCC, similar activation of serine synthesis following sunitinib treatment occurred in a variety of other cancer types, suggesting a shared adaptive response to sunitinib therapy. Together, this study identifies the de novo serine synthesis pathway as a potential target to overcome sunitinib resistance, offering insights into therapeutic strategies applicable across diverse cancer contexts.
A designed synthetic microbiota provides insight to community function in Clostridioides difficile resistance
Authors: Shuchang Tian, Min Soo Kim, Jingcheng Zhao, Kerim Heber, Fuhua Hao, David Koslicki, Sangshan Tian, Vishal Singh, Andrew D Patterson, Jordan E Bisanz
Journal: Cell Host & Microbe (2025)

Clostridioides difficile, a major cause of antibiotic-associated diarrhea, is suppressed by the gut microbiome, but the precise mechanisms are not fully described. Through a meta-analysis of 12 human studies, we designed a synthetic fecal microbiota transplant (sFMT1) by reconstructing microbial networks negatively associated with C. difficile colonization. This lab-built 37-strain consortium formed a functional community suppressing C. difficile in vitro and in animal models. Using sFMT1 as a tractable model system, we find that bile acid 7α-dehydroxylation is not a determinant of sFMT1 efficacy while one strain performing Stickland fermentation-a pathway of competitive nutrient utilization-is both necessary and sufficient for the suppression of C. difficile, replicating the efficacy of a human fecal transplant in a gnotobiotic mouse model. Our data illustrate the significance of nutrient competition in suppression of C. difficile and a generalizable approach to interrogating complex community function through robust methods to leverage publicly available sequencing data.
Impact of targeting the platelet-activating factor and its receptor in cancer treatment
Authors: Kimya Qaderi, Arvin Shahmoradi, Anita Thyagarajan, Ravi P. Sahu
Journal: Military Medical Research (2025)

Abstract The lipid mediator platelet-activating factor (PAF) and its receptor (PAFR) signaling play critical roles in a wide range of physiological and pathophysiological conditions, including cancer growth and metastasis. The ability of PAFR to interact with other oncogenic signaling cascades makes it a promising target for cancer treatment. Moreover, numerous natural and synthetic compounds, characterized by diverse pharmacological activities such as anti-inflammatory and anti-tumor effects, have been explored for their potential as PAF and PAFR antagonists. In this review, we provide comprehensive evidence regarding the PAF/PAFR signaling pathway, highlighting the effectiveness of various classes of PAF and PAFR inhibitors and antagonists across multiple cancer models. Notably, the synergistic effects of PAF and PAFR antagonists in enhancing the efficacy of chemotherapy and radiation therapy in several experimental cancer models are also discussed. Overall, the synthesis of literature review indicates that targeting the PAF/PAFR axis represents a promising approach for cancer treatment and also exerts synergy with chemotherapy and radiation therapy.
Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T Cell Immunotherapy
Authors: Rogelio A. Hernández-López, Tapio Kesti, Anna R. Mäkelä, Zhe Zhao, Wei Yu, Yurie Tonai, Hector J. Monzo, Kerttu Kalander, Sirpa Leppä, Päivi M. Ojala, Wendell A. Lim, Kalle Saksela
Journal: Cancer Research (2025)

Abstract Engineered T cell therapies have emerged as a promising approach for cancer treatment, yet their application to solid tumors remains challenging due to the limited specificity and persistence of current antigen recognition strategies. Here, we introduced sherpabodies, engineered from a human SH3 domain scaffold, as a class of antibody-mimetic proteins capable of precise tumor-associated antigen recognition. A phage display library identified sherpabodies against a panel of popular tumor-associated antigens (TAA), which were subsequently incorporated into second-generation chimeric antigen receptor constructs that were termed sherpabody-guided CARs (SbCARs). These SbCARs demonstrated potent in vitro specificity and cytotoxicity against solid cancer TAAs, without cross-reactivity to closely related proteins. The modularity, versatility, and small size of sherpabodies enabled generation of multipecific SbCARs, in particular TriSbCARs with OR-logic that could robustly activate with cells expressing any or combinations of three cognate TAA targets, as well as circuits with IF-THEN logic in combination with synthetic Notch. In vivo, SbCAR T cells elicited a dose-dependent antitumor response in xenograft mouse models, highlighting their potential for therapeutic application. Furthermore, an inducible SbCAR system displayed enhanced persistence and antitumor activity when compared to constitutive CARs. These findings suggest that sherpabodies represent a versatile and promising platform for the next generation of CAR-T cell therapies, particularly for solid tumors.
Effects of cigarette-derived compounds on the spread of antimicrobial resistance in artificial human lung sputum medium, simulated environmental media and wastewater
Authors: Peiju Fang, Diala Konyali, Emily Fischer, Robin Pascal Mayer, Jin Huang, Alan Xavier Elena, Gerit Hartmut Orzechowski, Andrew Tony-Odigie, David Kneis, Alexander Dalpke, Peter Krebs, Bing Li, Thomas U. Berendonk, Uli Klümper
Journal: Environmental Health Perspectives (2025)

Antimicrobial resistance (AMR) and smoking of tobacco products are two of the most important threats to global human health. Both are associated with millions of deaths every year. Surprisingly, the immediate interactions between these two threats are yet poorly understood.
Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems
Authors: Abigail L. Liberty, Maria I. Rodriguez, Alison Edelman
Journal: JAMA (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Breast Cancer and Levonorgestrel-Releasing Intrauterine Systems—Reply
Authors: Lina Steinrud Mørch, Amani Meaidi, Giulia Corn
Journal: JAMA (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel
Authors: Vaishali Dulobdas, Amy A. Kirkwood, Fabio Serpenti, Brijesh Gautama, Aikaterini Panopoulou, Amrith Mathew, Sumantha Gabriel, Ram Malladi, Jessica Pealing, Denise Bonney, Emma Nicholson, Caroline Besley, Sara Ghorashian, Andrea Kuhnl, Elizabeth Davies, Jackie Chappell, Anne Black, Tobias Menne, Maeve A. O’Reilly, Robin Sanderson, Sridhar Chaganti
Journal: Blood Cancer Journal (2025)

CAR T-cell manufacturing failure (MF) is a situation where the manufacturing process fails to yield a product or results in one which is out-of-specification (OOS). We conducted a multicentre retrospective review of factors contributing to MF and patient outcomes. Of 981 large B-cell lymphoma (LBCL) patients approved for CAR T-cell therapy, 38 (3.87%) had MF. Eleven patients received delayed infusion with a product in-specification (delayed-infused) following 21 remanufacturing attempts. OOS product was infused in 13 (OOS-infused), and 14 were not infused. For comparison, we included 38 LBCL controls without MF; 29 received infusion (controls-infused). Prior bendamustine was the only baseline variable associated with MF risk, largely due to therapy within 6 months; 23.7% MF vs 0% controls (P = 0.0029). Overall survival (OS) and progression-free survival (PFS) were not significantly different for infused patients, with 1-year OS (PFS) of 52.8% (46.2%), 46.8% (24.2%) and 68.4% (41.4%) for OOS-infused, delayed-infused and controls-infused respectively (PFS HR OOS-infused vs controls-infused 1.41, P = 0.40; delayed-infused vs controls-infused 1.64, P = 0.25; and OOS-infused vs delayed-infused 0.86, P = 0.76). CRS, ICANS and cytopenias were not significantly different between cohorts. Outcomes for OOS-infused LBCL patients following MF are encouraging. Remanufacturing led to infusion of a product in-specification in around 50% and may be an option for patients where a suitable OOS product is not available.
Cholesterol homeostasis and lipid raft dynamics at the basis of tumor-induced immune dysfunction in chronic lymphocytic leukemia
Authors: Chaja F. Jacobs, Fleur S. Peters, Elena Camerini, Gaspard Cretenet, Joanne Rietveld, Bauke V. Schomakers, Michel van Weeghel, Nico Hahn, Sanne G. S. Verberk, Jan Van den Bossche, Mirjam Langeveld, Fleur Kleijwegt, Eric Eldering, Noam Zelcer, Arnon P. Kater, Helga Simon-Molas
Journal: Cellular and Molecular Immunology (2025)

Abstract Autologous T-cell therapies show limited efficacy in chronic lymphocytic leukemia (CLL), where acquired immune dysfunction prevails. In CLL, disturbed mitochondrial metabolism has been linked to defective T-cell activation and proliferation. Recent research suggests that lipid metabolism regulates mitochondrial function and differentiation in T cells, yet its role in CLL remains unexplored. This comprehensive study compares T-cell lipid metabolism in CLL patients and healthy donors, revealing critical dependence on exogenous cholesterol for human T-cell expansion following TCR-mediated activation. Using multi-omics and functional assays, we found that T cells present in viably frozen samples of patients with CLL (CLL T cells) showed impaired adaptation to cholesterol deprivation and inadequate upregulation of key lipid metabolism transcription factors. CLL T cells exhibited altered lipid storage, with increased triacylglycerols and decreased cholesterol, and inefficient fatty acid oxidation (FAO). Functional consequences of reduced FAO in T cells were studied using samples from patients with inherent FAO disorders. Reduced FAO was associated with lower T-cell activation but did not affect proliferation. This implicates low cholesterol levels as a primary factor limiting T-cell proliferation in CLL. CLL T cells displayed fewer and less clustered lipid rafts, potentially explaining the impaired immune synapse formation observed in these patients. Our findings highlight significant disruptions in lipid metabolism as drivers of functional deficiencies in CLL T cells, underscoring the pivotal role of cholesterol in T-cell proliferation. This study suggests that modulating cholesterol metabolism could enhance T-cell function in CLL, presenting novel immunotherapeutic approaches to improve outcome in this challenging disease.